Adagio Medical Holdings (ADGM) Research & Development (2023 - 2026)

Adagio Medical Holdings (ADGM) has 4 years of Research & Development data on file, last reported at $2.7 million in Q1 2026.

• Research & Development for Q1 2026 came in at $2.7 million, down 25.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.7 million (down 13.28% YoY), and the FY2025 annual result was $10.6 million, up 129.59% from the prior year.
• Research & Development rose to $2.7 million in Q1 2026 per ADGM's latest filing, from $2.2 million in the prior quarter.
• Over five years, Research & Development peaked at $4.4 million in Q3 2023 and troughed at $1.2 million in Q3 2024.
• A 4-year average of $2.7 million and a median of $2.8 million in 2025 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2025: Research & Development sank 72.45% in 2024, then soared 127.94% in 2025.
• A 4-year view of Research & Development shows it stood at $1.8 million in 2023, then sank by 31.4% to $1.2 million in 2024, then soared by 83.65% to $2.2 million in 2025, then gained by 22.64% to $2.7 million in 2026.
• Business Quant data shows ADGM's Research & Development at $2.7 million in Q1 2026, $2.2 million in Q4 2025, and $2.8 million in Q3 2025.